Effect of preoperative intravenous iron therapy on transfusion requirements and morbidity in adult patients undergoing open heart surgery

Year 2026, Volume: 17 Issue: 57 , 59 - 65 , 16.04.2026

İbrahim Demir , Özlem Turhan , Türkan Tansel , Ufuk Alpagut , Onur Selçuk Göksel

https://doi.org/10.17944/interdiscip.1798695

https://izlik.org/JA74JW72FJ

Abstract

Objective: This study compared postoperative transfusion requirements, morbidity and mortality between adult cardiac surgery patients with preoperative anemia treated with intravenous ferric carboxymaltose and non-anemic patients.
Methods: This was a prospective study including 95 patients undergoing elective open heart surgery with cardiopulmonary bypass between April 2019 and April 2022. Twenty-five (26.3%) patients had preoperative iron deficiency anemia and received intravenous ferric carboxymaltose (1000 mg, with an additional 500 mg if indicated preoperatively based on BMI). Seventy patients were non-anemic controls. Transfusion criteria were based on hemoglobin < 7–8 g/dL, hemodynamic instability, or clinical judgment. Statistical analyses included Student’s t-test, Mann–Whitney U, Chi-square or Fisher’s exact tests with p<0.05 considered significant.
Results: Anemic patients received significantly more perioperative erythrocyte suspension (ES) and fresh frozen plasma (FFP) compared to non-anemic patients (p < 0.05). Postoperatively, there were no significant differences in ES/FFP use, ICU stay, intubation time, or hospital stay between groups (p > 0.05). The mean operation time was shorter in the anemic treated group, partly reflecting a lower CABG rate. Baseline demographics were similar across groups (mean age 61.6 ± 11.0 vs 60.2 ± 15.9 years).
Conclusion: Preoperative intravenous iron therapy in anemic patients did not reduce postoperative transfusion needs but allowed outcomes comparable to non-anemic patients. Intravenous (IV) iron therapy was safe, and patients experienced similar ICU and hospital courses. Larger randomized controlled trials are required to confirm efficacy.

Keywords

Transfusion , Open Heart Surgery , Anemia

Ethical Statement

Ethical Approval has been declared as a supplementary file

Supporting Institution

None

References

• DeLoughery TG. Iron Deficiency Anemia. Med Clin North Am. 2017;101(2):319-332. doi: 10.1016/j.mcna.2016.09.004. Epub 2016 Dec 8.
• Bellakhal S, Ouertani S, Antit S, Abdelaali I, Teyeb Z, Dougui MH. Iron deficiency anemia: clinical and etiological features. Tunis Med. 2019;97(12):1389-1398.
• Hubert M, Gaudriot B, Biedermann S, Gouezec H, Sylvestre E, Bouzille G, Verhoye JP, Flecher E, Ecoffey C. Impact of Preoperative Iron Deficiency on Blood Transfusion in Elective Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019;33(8):2141-2150. doi: 10.1053/j.jvca.2019.02.006.
• Scott BH, Seifert FC, Glass PS, Grimson R. Blood use in patients undergoing coronary artery bypass surgery: impact of cardiopulmonary bypass pump, hematocrit, gender, age, and body weight. Anesthesia & Analgesia. 2003;97(4):958-63. https://doi.org/10.1213/01.ANE.0000081790.75298.D8
• Horvath KA, Acker MA, Chang H, Bagiella E, Smith PK, Iribarne A, et al. Blood transfusion and infection after cardiac surgery. Ann Thorac Surg. 2013;95(6):2194-201. doi: 10.1016/j.athoracsur.2012.11.078. E
• Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34(6):1608-16. doi: 10.1097/01.CCM.0000217920.48559.D8.
• Licker M, Ellenberger C, Sierra J, Christenson J, Diaper J, Morel D. Cardiovascular response to acute normovolemic hemodilution in patients with coronary artery diseases: Assessment with transesophageal echocardiography. Crit Care Med. 2005;33(3):591-7. doi: 10.1097/01.ccm.0000156446.03285.e0.
• Loor G, Li L, Sabik JF 3rd, Rajeswaran J, Blackstone EH, Koch CG. Nadir hematocrit during cardiopulmonary bypass: end-organ dysfunction and mortality. J Thorac Cardiovasc Surg. 2012;144(3):654-662.e4. doi: 10.1016/j.jtcvs.2012.03.058.
• Ranucci M, Conti D, Castelvecchio S, Menicanti L, Frigiola A, Ballotta A, et al. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg. 2010;89(1):11-7. doi: 10.1016/j.athoracsur.2009.07.078.
• Swaminathan M, Phillips-Bute BG, Conlon PJ, Smith PK, Newman MF, Stafford-Smith M. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg. 2003;76(3):784-91; discussion 792. doi: 10.1016/s0003-4975(03)00558-7.
• Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544-52. doi: 10.1161/CIRCULATIONAHA.107.698977.
• Roman MA, Abbasciano RG, Pathak S, Oo S, Yusoff S, Wozniak M, et al. Patient blood management interventions do not lead to important clinical benefits or cost-effectiveness for major surgery: a network meta-analysis. Br J Anaesth. 2021;126(1):149-156. doi: 10.1016/j.bja.2020.04.087.
• Günaydın S, Spahn DR, Özışık K, Demir A, Aşkın G, Sert DE, et al. Building a patient blood management program in a large-volume tertiary hospital setting: Problems and solutions. Turk Gogus Kalp Damar Cerrahisi Derg. 2020;28(3):560-569. doi: 10.5606/tgkdc.dergisi.2020.19701.
• Tatar M, Alkış N, Yıldırım Güçlü Ç, Bermede O, Erdemli B, Günaydın S. Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System. Clinicoecon Outcomes Res. 2022;14:415-426. doi: 10.2147/CEOR.S360944.
• Özhan A, Akgül E, Parlar Aİ, Çekirdekçi A. The association of blood transfusion and acute kidney injury in diabetic coronary artery bypass grafting patients. Cardiovasc Surg Int. 2021;8(1):13-19. doi: 10.5606/e-cvsi.2021.1065.
• Köseoğlu FD, Daylan A, Rahman ÖF, Cansu D, Metehan EO, Bozok Ş. Short-term preoperative intravenous iron replacement: Impact on surgical outcomes in cardiovascular disease. Cardiovasc Surg Int. 2024;11(1):42-51. doi: 10.5606/e-cvsi.2024.1635.